Zydus Cadila receives approval for Baclofen Tablets

Shohini Nath
/ Categories: Trending, Markets

Zydus Cadila has received the final USDFA approval for Baclofen Tablets, 10mg and 20mg. The shares of the company, however fell intraday.

The United States Food and Drug Administration has granted Zydus Cadila to manufacture Baclofen Tablets at the group’s formulations manufacturing facility at Baddi, Himachal Pradesh. Baclofen works by helping to relax the muscles, thus treating muscle spasms that are generally caused by certain conditions such as multiple sclerosis or spinal cord injury.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

On Tuesday, the shares of Cadila Healthcare opened at Rs. 356 per share as against Monday’s close of Rs 353.25. At 15:15 hours, the shares of the company were trading at Rs 344.55, down by 2.46 per cent or by 8.70 points. The intraday high was Rs. 356.90 and intraday low was Rs. 342.90 per share on the BSE. Its 52-week high was Rs. 456.10 and 52-week low was Rs. 330.65 per share on the BSE.

Meanwhile, the BSE Sensex was at 35,509.39 level, up by 0.44 per cent and the Nifty50 was at 10,682.75, up by 0.51 per cent.


Previous Article Alembic Pharma gains on receiving USFDA approval for Temazepam Capsules
Next Article IIFL Securities to buy stake in Trendlyne
Rate this article:
5.0

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR